USPTO serial 97907917
MURAL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- TANNER, MICHAEL R
- Law office
- TMO LAW OFFICE 119
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with MURAL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Norm J. Rich
Norm J. Rich FOLEY & LARDNER LLP3000 K STREET, N.W.SIXTH FLOORWASHINGTON, DC 20007Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Therapeutic proteins for use in the manufacture of pharmaceutical preparations | ACTIVE | — |
| 005 | Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer | ACTIVE | — |
| 042 | Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology | ACTIVE | — |
| 044 | Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Alkermes Pharma Ireland Limited
- Other trademarks owned by MURAL ONCOLOGY, INC.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MURAL
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 14, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 23, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 23, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 23, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 12, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Oct 29, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 28, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 28, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 28, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 28, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 28, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 28, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 28, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 28, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 12, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 12, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 12, 2024 | ALIE | ASSIGNED TO LIE | — |
| Apr 23, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 28, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 25, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 25, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 23, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| May 24, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 1, 2023 | NWAP | NEW APPLICATION ENTERED | — |